Haematopoietic SCT is currently considered a therapeutic option mainly in relapsed or refractory non-Hodgkin's lymphoma (NHL) owing to high post-transplantation relapse rates and significant toxicity of conventional myeloablative conditioning for allogeneic SCT. Radiolabelled immunotherapy combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, and is a promising advance in the treatment of malignant lymphomas. It is now under investigation as a component of conditioning prior to SCT, with the aim of improving outcomes following SCT without increasing the toxicity of high-dose chemotherapy pretransplant conditioning. An expert panel met at a European workshop in November 2006 to review the latest data on radiolabelled immunotherapy in the transplant setting, and its potential future directions, with a focus on 90 Y-ibritumomab tiuxetan. They reviewed data on the combination of standard/high/escalating dose 90 Yibritumomab tiuxetan with high-dose chemotherapy, and high/escalating dose 90 Y-ibritumomab tiuxetan as the sole myeloablative agent, prior to autologous SCT, and also 90 Y-ibritumomab tiuxetan as a component of reduced intensity conditioning prior to allogeneic SCT. The preliminary data are highly promising in terms of conditioning tolerability and patient outcomes following transplant; further phase II studies are now needed to consolidate these data and to investigate specific patient populations and NHL subtypes.
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Introduction
In non-Hodgkin's lymphoma (NHL), haematopoietic SCT is primarily considered as a therapeutic option for relapsed or refractory patients, who have a poor prognosis with conventional salvage chemotherapy. It is also occasionally used as an initial treatment in some younger high-risk patients, although there are controversies over the clinical evidence indicating that outcomes are better versus conventional chemotherapy. A variety of conditioning regimens, which aim to eliminate or reduce cancer cells prior to transplant, have been investigated. Myeloablative conditioning traditionally comprises high-dose chemotherapy (HDC) with or without TBI but is associated with toxicity, which limits its use in certain patient groups such as the elderly. Moreover, there is still a significant relapse rate post-transplantation, indicating that eradication of tumour cells is incomplete or that there is a lack of GvL effect after allograft. The combination of rituximab immunotherapy with conventional chemotherapy regimens led to improvements in response rates in NHL, and now radiolabelled immunotherapy, which combines the benefits of monoclonal antibody targeting with therapeutic doses of radiation, is promising to be a major step forward in the treatment of malignant lymphomas. The improved tolerability of radiolabelled immunotherapy plus HDC compared with TBI plus HDC may allow transplantation in a wider patient group in the future than was previously feasible. This article reviews the latest data on yttrium-90 ( 90 Y)-ibritumomab tiuxetan (Zevalin, Bayer Schering Pharma AG, Berlin, Germany) in both autologous and allogeneic SCT for NHL, and summarizes the outcomes of a European workshop held to discuss the potential future role for 90 Y-ibritumomab tiuxetan in transplantation conditioning regimens.
Current concepts in SCT in NHL
The treatment of NHL and the role of SCT Non-Hodgkin's lymphoma is a heterogeneous group of lymphoid malignancies that most commonly occur in individuals over the age of 60 years. Aggressive (highgrade) subtypes progress rapidly but are potentially curable, whereas indolent (low-grade) subtypes are slower growing but usually relapse after conventional treatment. The introduction of immunotherapy, and its combination with chemotherapy, greatly improved remission rates compared with chemotherapy alone in NHL, and more recently, the combination of immunotherapy plus 90 Y or iodine-131 ( 131 I) radiation has shown much greater efficacy than immunotherapy alone and may improve overall survival (OS).
The greatest challenge in NHL is keeping patients in remission once they respond to therapy. Following induction therapy, options for consolidation therapy include chemotherapy and SCT, with or without maintenance therapy; SCT permits higher doses of chemotherapy to be used.
Outcomes of SCT in NHL
High-dose chemotherapy conditioning and autologous SCT now have an established role in patients in first chemosensitive relapse of aggressive NHL, resulting in estimated 5-year disease-free survival rates of 40-50%, 1 and significantly higher survival rates versus chemotherapy alone. 2 There is still controversy over the use of HDC and SCT as consolidation first-line in poor-prognosis aggressive lymphoma. Several phase III studies prior to the rituximab era suggested an improvement in event-free survival (EFS) in poor-prognosis follicular lymphoma (FL). In a recent phase III trial comparing the efficacy of rituximab plus standard chemotherapy (R-CHOP) with rituximab plus HDC and autologous SCT (R-HDC-SCT) as first-line therapy in poor-risk FL patients, preliminary data indicated better EFS and progression-free survival (PFS) in the R-HDC-SCT arm. No differences were observed in terms of OS at that time, although the trial was not designed to assess this. 3 A clinical study evaluating rituximab administration after autologous (n ¼ 16) or allogeneic (n ¼ 12) SCT in patients at high risk for post-transplant relapse indicated that rituximab may be effective in reducing the relapse rate and improving outcome in high-risk aggressive lymphoma. Of 24 patients receiving rituximab starting at a median of 47 days post-transplant, 9 patients converted to a CR. Onset of GvHD was observed in three patients. At a median follow-up of 12 months the estimated 2-year OS rate was 95%, the disease-free survival rate was 64% and the relapse rate was 35%. 4 Autologous SCT was previously not carried out in elderly patients owing to their expected inability to tolerate myeloablative conditioning regimens. Some studies have shown no differences in outcome between older and younger patients [5] [6] [7] [8] with the exception of cardiac toxicity and renal impairment, which may be higher in elderly patients; 9 however, it should be noted that transplant is only possible in selected patients over the age of 65 years, that is, those fulfilling all of the eligibility criteria for transplant. Transplant-related mortality (TRM) is low for autologous SCT, with rates below 5%. 10 However, autologous transplantation has only limited success when performed in the refractory or progressive stages of lymphoma and in heavily pre-treated or multiply relapsed patients.
Allogeneic transplantation has the advantage of providing a tumour-free graft and the additional benefit of a potent GvL anti-tumour effect, allowing potential cure even in low-grade and advanced lymphoma patients, albeit at the cost of higher morbidity and mortality derived from the development of GvHD. It is generally considered for younger patients for whom there is a suitable donor, and may also offer an alternative in patients not suitable for, or having relapsed after, autologous SCT. Retrospective multi-centre studies suggest that relapse rates and PFS are better following allogeneic transplant compared to autologous SCT in NHL, with cure rates of around 20-40%, [11] [12] [13] although prospective, randomized trials are needed to confirm this. Conventional high-dose myeloablative conditioning (cyclophosphamide plus TBI or busulphan) is associated with high toxicity and TRM rates of up to 40%. 10 However, TRM associated with allogeneic SCT is steadily being reduced, particularly with the introduction of reduced-intensity conditioning (RIC) regimens. 12 RIC regimens use lower doses of chemotherapy and radiation, allowing engraftment of donor cells with reduced toxicity compared to myeloablative regimens. Most are fludarabine-based and include TBI or other agents such as melphalan. 4, [14] [15] [16] [17] RIC regimens shift the burden of tumour-killing from chemotherapy to the GvL effect mediated by donor T cells; therefore, efficacy is dependant on the immune response to the donor cells and a longer time may be required to achieve remission. Allogeneic SCT after RIC is therefore more suitable for indolent lymphomas. Aggressive lymphomas often progress or relapse before the anti-lymphoma effect develops and are therefore better suited to conventional high-dose myeloablative conditioning. RIC is generally carried out in patients already in remission; as the conditioning is not myeloablative, the risk of relapse is high if the patient has not achieved a CR or very good PR before SCT. 18 The reduced toxicity and better tolerability of RIC regimens also allow SCT in older patients and in those with comorbidities or contraindications to conventional regimens. To date there are no randomized comparisons of conventional and RIC regimens and further data are awaited to confirm the best conditioning regimen in different patient groups. Rationale for using 90 Y-ibritumomab tiuxetan in SCT Lymphomas are inherently radiosensitive, providing a rationale for using radiation to treat NHL, and the targeted delivery of radiation directly to tumour sites is better tolerated and more efficient than TBI. The principles of radiolabelled immunotherapy, which allows targeted delivery of a therapeutic dose of radiation not only to the surface of tumour cells at multiple sites but also to neighbouring deeper cells, have been reviewed extensively in recent publications. [19] [20] [21] [22] The only radiolabelled immunoconjugates currently approved for the treatment of NHL are 90 Y-ibritumomab tiuxetan and 131 I-tositumomab (Bexxar, GlaxoSmithKline, USA; only approved in the United States), both of which are directed against the CD20 cell surface antigen.
Autologous and allogeneic SCT in Europe
90 Y-ibritumomab tiuxetan comprises the anti-CD20 monoclonal antibody, ibritumomab, conjugated via the tiuxetan chelator to the pure b-emitting radioisotope yttrium-90 ( Y-ibritumomab tiuxetan in the conditioning regimen prior to autologous SCT in refractory, aggressive NHL expected to have poor outcome with standard conditioning (Table 1) . In this study, reduced cell counts and extensive bone marrow involvement were not exclusion criteria. Presence of active disease was determined using positron emission tomography and computed tomography (PET-CT) scanning. Overall, 11 patients had primary refractory disease, 12 had refractory relapsed disease and 14 had bulky disease at transplant. Patients received the Z-BEAM conditioning regimen, comprising Table 1 Selected ongoing phase I/II studies of standard-dose radiolabelled immunotherapy plus high-dose BEAM prior to autologous SCT Y-ibritumomab tiuxetan 0.4 mCi/kg (Z) on day À14 followed by BCNU, etoposide, ara-C, melphalan (BEAM) starting on day 6. All patients engrafted rapidly, in a median of 10 days (range, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , indicating that 90 Y-ibritumomab tiuxetan had no impact on engraftment kinetics. Overall 16 of 21 evaluable patients achieved a CR (76%): 11 achieved a CR, 9 achieved a PR, of whom 5 converted to CR with additional radiation therapy to eliminate residual disease. After a median follow-up of 17 months (range, 6-27 months) 16 of 23 patients were alive. A total of seven patients relapsed or did not respond and, as expected with refractory disease, all relapses occurred within 6 months of SCT. The cumulative incidence of relapse was relatively low for patients with refractory disease, and the OS and PFS rates compared very favourably with the expected rates (o20%) for standard autologous SCT in this patient group. Nonrelapse mortality at day 100 in these heavily pre-treated refractory patients was 9% (95% confidence interval (CI), 2-33). The median first day of neutropenia was day 2 (range, À3 to 4); however, nine patients became neutropenic prior to or on the day of SCT, which is an uncommon occurrence with standard BEAM. Two patients with very large abdominal masses died of multi-organ toxicities early after transplant. The only NCI grade IIIÀIV toxicities were massive gastrointestinal bleeding (n ¼ 1) and severe gastritis (n ¼ 1). Both patients had extensive lymphomatous infiltration of the stomach at the time of SCT but recovered completely. In addition, one patient died of septic shock 4 months after SCT and one of bronchiolitis obliterans (probably infection-related) 5 months after SCT. There was no apparent additional toxicity related to the use of 90 Yibritumomab tiuxetan and the investigators concluded that its inclusion in this conditioning regimen was relatively safe and improved outcomes in patients with refractory lymphoma.
The Groupe d'É tude des Lymphomes de l'Adulte (GELA) in France also investigated Z-BEAM conditioning prior to autologous SCT in patients with relapsing lowgrade NHL (unpublished data). Patients had to have experienced a relapse after CR, stable disease (SD) or PR with no more than three prior chemotherapy treatments with or without rituximab, and be chemosensitive to salvage therapy. The study protocol is shown in Figure 1 . The interim safety analysis is presented here. After the last pre-transplant salvage treatment the response rates of these patients were nine CR (31%), thirteen CRu (unconfirmed CR; 45%) and seven PR (24%). The median dose of 90 Y-ibritumomab tiuxetan administered was 27.8 mCi (range, 19.2-34.9 mCi). Preliminary results show that following SCT, time to engraftment was rapid (independent of transfusion), with a better, sustained haematological reconstitution at day 100 compared with a matched control group of low-grade lymphoma patients receiving TBI in a conditioning regimen prior to autologous SCT. At day 100 post-transplant WBC was 4700/mm 3 in the 90 Y-ibritumomab tiuxetan group versus 2950/mm 3 in the TBI group (P ¼ 0.04), platelets were 136 000 versus 85 000/mm 3 , respectively, and Hb 14 versus 11.25 g/dl (P ¼ 0.0023), respectively. In terms of toxicity, 83% of patients experienced grade III-IV infections and 48% mucositis. There were no toxicity-related deaths. These preliminary results suggest that Z-BEAM is a well-tolerated and effective regimen for older patients with poor-risk NHL undergoing autologous SCT.
Two further studies of standard-dose 90 Y-ibritumomab tiuxetan in the conditioning regimen prior to autologous SCT are ongoing, and are described in Table 1 Y-ibritumomab tiuxetan conditioning (median 71.6 mCi) for autologous SCT in combination with high-dose etoposide and cyclophosphamide in 31 patients with CD20-positive NHL. Patients underwent dosimetry followed 1 week later by 90 Y-ibritumomab tiuxetan to deliver a target dose of 1000 cGy to normal organs. This conditioning regimen appeared to be well tolerated, with the most common treatment-related toxicities being mucositis (100%), neutropenic fever (96%) and rash (90%). Engraftment of transplanted cells was rapid, and OS and PFS rates were high ( Table 2 ). The investigators concluded that high-dose 90 Y-ibritumomab tiuxetan could be safely combined with high-dose etoposide and cyclophosphamide without any increase in transplant-related toxicity or any delay in engraftment. Escalating-dose 90 Y-ibritumomab tiuxetan (0.3-1.2 mCi/ kg) plus high-dose BEAM was investigated in a phase I trial of relapsed or refractory CD20-positive NHL. [33] [34] [35] Based on dosimetry results, patient-specific doses of 90 Y-ibritumomab tiuxetan calculated to deliver escalating radiation doses (300-2100 cGy) to critical organs (liver, lung or kidney) were administered. The median age of the patients was 54 years (range, 25-72 years) and most had received three or more treatment regimens, including rituximab. The toxicity profile of the 90 Y-ibritumomab tiuxetan-containing conditioning regimen was similar to that seen with high-dose BEAM alone. The most common grade III/IV toxicities were infection, fever, stomatitis, nausea, vomiting, diarrhoea, haemorrhage and oedema. Engraftment was rapid and 3-year OS and PFS rates were good (Table 2) .
Studies investigating high-dose 131 I-tositumomab have also been published (Table 2) . 36, 37 High-dose and escalated-dose 90 Y-ibritumomab tiuxetan monotherapy 90 Y-labelled immunotherapy alone as a conditioning regimen may be a therapeutic option for elderly patients who are unable to tolerate HDC conditioning prior to SCT, patients with chemoresistant disease and patients relapsing after conventional autologous SCT.
A pilot study was undertaken by Devizzi and colleagues 38, 39 to evaluate the feasibility and toxicity of myeloablative 90 Y-ibritumomab tiuxetan doses with tandem stem cell support in a prospective cohort of 29 refractory or relapsed NHL patients. Prior to 90 Y-ibritumomab tiuxetan, all patients received three cycles of standard-dose salvage chemotherapy followed by one cycle of high-dose cyclophosphamide plus rituximab, and one cycle of high-dose cytarabine plus rituximab, at patient-adapted doses.
90 Yibritumomab tiuxetan was administered at a dose of 0.8 mCi/kg (n ¼ 13) or 1.2 mCi/kg (n ¼ 16) followed by tandem autografting of peripheral blood stem cells on days þ 7 and þ 14. Re-infusion was performed in the presence of potentially myelotoxic radioactivity at day 7 after radiolabelled immunotherapy to induce an immediate, albeit transient, haematopoietic recovery; another infusion was performed on day 14 when the radiation-absorbed dose to the stem cells was estimated to be o5 cGy, thus ensuring a long-lasting haematopoietic recovery.
Toxicity was as expected, but notably, there was an absence of the most frequent severe complications normally seen with conventional HDC. Grade IV neutropenia was observed in 13 patients (45%), and only lasted a median of 4 days (range, 1-14 days). Grade IV thrombocytopenia occurred in 19 patients (65%) for a median duration of 5 days (range, 1-14 days). Fifteen patients (52%) required platelet transfusions and fourteen patients (48%) underwent one red blood cell transfusion each. No extrahaematologic toxicity was observed except for mild nausea in 17% of the patients, and all but three patients were cared for as outpatients. Two-year OS and PFS rates were high (Table 3) . These positive results suggest that high-dose 90 Y-ibritumomab tiuxetan with tandem SCT would be a valuable conditioning regimen in a pre-treated and elderly patient population as it showed minimal toxicity, with the added advantage that it can be used in an outpatient setting. Efficacy remains to be defined in comparison to conventional HDC and standard-dose 90 Y-ibritumomab tiuxetan (0.4 mCi/kg).
High-dose 90 Y-ibritumomab tiuxetan monotherapy plus peripheral blood stem cell support has also been investigated by Vanazzi and colleagues [40] [41] [42] in a phase I/II study of refractory or chemoresistant NHL patients. Following dosimetry, patients received 0.8, 1.2 or 1.5 mCi/kg 90 Yibritumomab tiuxetan. Dosimetry showed acceptable radiation-absorbed doses to critical normal organs in all cases. All but one patient engrafted promptly, defined as an Table 2 Selected ongoing phase I/II studies of dose-escalated radiolabelled immunotherapy plus high-dose chemotherapy prior to autologous SCT absolute neutrophil count 41.0 Â 10 9 per litre or platelet count 420 Â 10 9 per litre on day 28 after SCT. Nonhaematologic toxicity was as expected and relatively mild, with no pulmonary, renal or cardiac toxicity observed. Responses were seen in 60% patients (Table 3) , demonstrating that 90 Y-ibritumomab tiuxetan at myeloablative doses is a feasible treatment with peripheral blood stem cell support, and may be suitable for elderly and heavily pretreated patients, including those who have previously received HDC. The investigators suggest an activity of 1.5 mCi/kg is suitable for those patients with normal platelet counts, while 1.2 mCi/kg could be considered for patients with a platelet count o150 Â 10 9 .
Further support for the use of 90 Y-ibritumomab tiuxetan monotherapy and autologous SCT has been provided by a study by Flinn and colleagues. 43, 44 They found that significant dose escalation could be achieved, with a range of doses (20-143 mCi) being given in outpatient setting. Autologous SCT was performed when the estimated radiation dose to the bone marrow was o1 cGy per hour. All patients engrafted rapidly and at day 60 post-SCT the overall response rate was 81% (Table 3) .
A number of studies investigating 131 I-tositumomab monotherapy for conditioning prior to SCT have also been carried out, and are described in Table 3 . [45] [46] [47] [48] [49] [50] Tolerability These preliminary data indicate that 90 Y-ibritumomab tiuxetan at standard and high/escalating doses was well tolerated as a component of transplant conditioning regimens. Toxicity profiles were similar to those seen with other high-dose regimens such as TBI, etoposide and cyclophosphamide, with no additional toxicity and no AEs or allergic reactions specifically attributed to 90 Y-ibritumomab tiuxetan. AEs observed following 90 Y-ibritumomab tiuxetan plus HDC and transplant were as expected and included skin rashes, nausea/vomiting, mucositis, infection, cardiac, pulmonary and hepatic toxicity. In studies where 90 Y-ibritumomab tiuxetan was the sole myeloablative agent, AEs were as expected for monotherapy (neutropenia, infections) and were relatively mild, and the most frequent, severe complications normally seen with conventional HDC conditioning were not observed. Tolerability findings were similar in 131 I-tositumomab studies; abnormal levels of thyroid-stimulating hormone were also frequently observed following 131 I-tositumomab-based conditioning. Conventional chemotherapy for NHL, such as alkylating agents, is associated with an increased risk of myelodysplastic syndrome (MDS) and acute myelogenous leukaemia (AML). They usually develop within 10 years of treatment exposure and are associated with a poor prognosis. One Table 3 Selected ongoing phase I/II studies of dose-escalated radiolabelled immunotherapy as sole myeloablation prior to autologous SCT I tositumomab as single-agent firstline therapy with a median follow-up of almost 5 years. 54 Current and future directions for the use of 90 Y-ibritumomab tiuxetan in autologous SCT There is still a substantial need to further improve conditioning regimens in SCT through a safe treatment modality. The high relapse rates observed after autologous SCT suggest that most conditioning regimens are inadequate and therefore more effective options are needed. Radiolabelled immunotherapy, in particular 90 Y-ibritumomab tiuxetan, has shown great promise as part of conditioning regimens both as high-dose monotherapy, and at standard and escalated doses alongside HDC, and appears to offer an effective and well-tolerated alternative to TBI. Future research to evaluate the role of 90 Yibritumomab tiuxetan alone with peripheral blood stem cell support should take a stepwise approach, focusing initially on phase II studies in patients with different histological NHL subtypes, but including clear eligibility criteria to define an homogenous population of lymphoma patients; those with a poor prognosis, and also as first-line therapy and following relapse. Subsequently, these results can be compared with standard regimens in historical controls before making the decision to move on to randomized studies in poor-prognosis NHL patients. Table 4 . The TRM rate is two patients so far and GvHD grade II-IV occurred in 43% of patients. Ten patients achieved a CR and three achieved a PR. Thirteen of sixteen evaluable patients are alive and well. These findings suggest that radiolabelled immunotherapy as part Y-ibritumomab tiuxetan in stem cell transplant C Gisselbrecht et al of an RIC regimen is feasible, engraftment is fast and there is no added toxicity.
Shimoni and colleagues 56, 57 have also investigated 90 Yibritumomab tiuxetan as part of an RIC regimen using either fludarabine/melphalan or fludarabine/busulphan prior to allogeneic SCT in patients with chemorefractory aggressive NHL (Table 4) . Patients were eligible for inclusion if they did not achieve a CR with prior chemotherapy (either as initial treatment or after relapse) and had active lymphoma by PET-CT scan, or if they had relapsed after a prior autologous SCT. Median age was 54 years (range, 37-62 years) and median time from diagnosis was 38 months (range, 9-96 months). The median number of prior therapies was 4 (range, 2-6) and four patients had a prior autologous SCT. One patient had primary refractory disease and eleven had relapsed refractory disease. Allogeneic SCT was performed using an HLA-matched sibling donor in seven patients, a one-antigen mismatched related donor in one patient and a matched unrelated donor in four patients. Prophylaxis against GvHD was given using cyclosporin from day À1, methotrexate 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6. Immunosuppression was withdrawn early (before 3 months) in patients who did not show signs of GvHD. All patients engrafted in a median of 14 days (range, 10À22) and 90 Y-ibritumomab tiuxetan had no impact on engraftment kinetics. Of the nine patients evaluable for response, five achieved a CR and four a PR. After a median follow-up of 9 months (range, 1-27 months), six patients were alive, and six had died (one early death due to multi-organ toxicity). The 1-year cumulative incidence of relapse was relatively low for patients with refractory disease, suggesting that this regimen has an additional anti-lymphoma effect. Two patients relapsed, but as expected from refractory disease, these occurred within a very short time after transplantation. The cumulative incidence of acute GvHD grade III-IV was 60% (95% CI, 36-100%) and due to this high incidence of severe acute GvHD the rate of non-relapse mortality was relatively high at 46% (95% CI, 21-100%). This was probably related to the planned early withdrawal of immunosuppression in patients with active disease and expected poor prognosis. The investigators suggested that better results might be achieved in patients transplanted earlier in the disease course and with a longer duration of immune suppression. This study confirms that the inclusion of 90 Y-ibritumomab tiuxetan in RIC prior to allogeneic SCT is feasible with no impairment in engraftment and relatively low organ toxicity in heavily pre-treated patients with refractory NHL.
Gopal et al. 58 undertook a phase II trial enrolling relapsed or refractory NHL patients who were not eligible for a traditional myeloablative transplant but had lymphoma that was too high risk for a routine non-ablative transplant. The median number of prior regimens was 6 and five patients had previous autologous transplant. 90 Yibritumomab tiuxetan on day À14 was combined with an RIC regimen using fludarabine and 2 Gy TBI. Cyclosporin and mycophenolate mofetil were administered as GvHD prophylaxis. There were no non-relapse-related deaths in the first 100 days, no graft rejections or failures, and all patients achieved 480% donor chimerism by 28 days after transplant. Three patients achieved a CR and four achieved a PR, including one CR, six PR and three SD by 1 month after transplant. Outcomes are shown in Table 4 . Reduced-intensity conditioning regimens used prior to allogeneic SCT may not be intensive enough to control the tumour during the period while the immune response is being established. It is likely that radiolabelled immunotherapy will have a role to play in boosting the anti-tumour effect during RIC with acceptable toxicity. Phase II studies to evaluate 90 Y-ibritumomab tiuxetan in this setting are now warranted. Table 4 Ongoing studies of radiolabelled immunotherapy in RIC prior to allogeneic SCT 
Conclusions
Monoclonal antibodies have now become established components of therapeutic regimens to combat haematological malignancies due to their targeted efficacy. The development of radiolabelled immunotherapies such as 90 Y-ibritumomab tiuxetan has capitalized on this targeted approach with the added power of delivering therapeutic doses of radiation to disseminated tumour sites. In a number of independent studies in the transplant setting, 90 Y-ibritumomab tiuxetan has been shown to have a promising role as a component of conditioning regimens, not only to augment standard chemotherapy regimens (immunotherapy-enhanced conditioning), but also as the sole conditioning agent, extending the option of transplantation to a wider range of patients. In autologous SCT, the use of 90 Y-ibritumomab tiuxetan in combination with HDC has no effect on the speed of engraftment and has a toxicity profile similar to conventional conditioning regimens. As a monotherapy conditioning regimen, high-dose 
